Stemline Therapeutics Company Profile (NASDAQ:STML)

About Stemline Therapeutics (STML)

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: STML
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $9.05
  • 50 Day Moving Average: $8.79
  • 200 Day Moving Average: $10.30
  • 52-Week Range: $4.79 - $14.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.27
  • P/E Growth: 0.00
  • Market Cap: $159.76M
  • Outstanding Shares: 17,951,000
  • Beta: 0.13
Profitability:
  • Net Margins: -4,058.44%
  • Return on Equity: -50.06%
  • Return on Assets: -44.60%
Debt:
  • Current Ratio: 5.60%
  • Quick Ratio: 5.60%

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.80 (201.12% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017HC WainwrightReiterated RatingBuy$34.00LowView Rating Details
3/25/2017WedbushReiterated RatingOutperform$11.00LowView Rating Details
3/23/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/20/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$41.00MediumView Rating Details
2/3/2017Jefferies Group LLCSet Price TargetBuy$16.00N/AView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 4/29/2015 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)
Earnings History by Quarter for Stemline Therapeutics (NASDAQ:STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
2017 EPS Consensus Estimate: ($1.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Stemline Therapeutics (NASDAQ:STML)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 37.76%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Stemline Therapeutics (NASDAQ:STML)
Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
Source:
DateHeadline
americanbankingnews.com logoStemline Therapeutics (STML) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 8:46 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and ... - PR Newswire (press release)
www.prnewswire.com - April 25 at 9:35 AM
americanbankingnews.com logoStemline Therapeutics (STML) Receives Daily News Sentiment Score of 0.16
www.americanbankingnews.com - April 24 at 7:22 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Stemline Therapeutics (STML) Stock Price
www.americanbankingnews.com - April 21 at 11:00 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 21 at 7:24 PM
americanbankingnews.com logoStemline Therapeutics (STML) Given Daily News Impact Score of 0.23
www.americanbankingnews.com - April 18 at 3:38 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 12:28 PM
americanbankingnews.com logoStemline Therapeutics (STML) Given Media Impact Score of 0.23
www.americanbankingnews.com - April 15 at 3:17 PM
finance.yahoo.com logoDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoSTEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND …
finance.yahoo.com - April 1 at 10:14 AM
globenewswire.com logoUPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
finance.yahoo.com logoApril 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoDEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoSTML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoUPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoAPRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, …
finance.yahoo.com - March 31 at 1:30 AM
us.rd.yahoo.com logoDeadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
us.rd.yahoo.com - March 31 at 1:30 AM
feeds.benzinga.com logoAPRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - March 30 at 10:06 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - March 30 at 8:29 PM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 8:29 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 2:07 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Stemline Therapeutics, Inc.
finance.yahoo.com - March 28 at 7:55 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 28 at 12:28 PM
americanbankingnews.com logoShort Interest in Stemline Therapeutics Inc (STML) Grows By 43.3%
www.americanbankingnews.com - March 28 at 7:13 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 27 at 7:14 PM
americanbankingnews.com logoStemline Therapeutics' (STML) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 25 at 10:59 AM
streetinsider.com logoStemline Therapeutics (STML) Completes Enrollment in Stage 3 of ... - StreetInsider.com
www.streetinsider.com - March 25 at 5:40 AM
finance.yahoo.com logoSTEMLINE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Stemline Therapeutics, Inc. – (STML)
finance.yahoo.com - March 25 at 5:40 AM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - March 24 at 7:55 PM
us.rd.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
us.rd.yahoo.com - March 24 at 7:55 PM
us.rd.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 24 at 7:55 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Given a $41.00 Price Target by Ladenburg Thalmann Financial Services Analysts
www.americanbankingnews.com - March 24 at 8:05 AM
streetinsider.com logoStemline Therapeutics (STML) Completes Enrollment in Stage 3 of SL-401 Pivotal Trial in BPDCN
www.streetinsider.com - March 24 at 1:44 AM
finance.yahoo.com logoStemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN
finance.yahoo.com - March 24 at 1:44 AM
finance.yahoo.com logoSTEMLINE THERAPEUTICS INC Financials
finance.yahoo.com - March 24 at 1:44 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Stemline Therapeutics, Inc. Of Imminent Lead Plaintiff Deadline
finance.yahoo.com - March 24 at 1:44 AM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 23 at 11:50 AM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - March 23 at 11:38 AM
americanbankingnews.com logoStemline Therapeutics' (STML) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 23 at 10:05 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.
finance.yahoo.com - March 22 at 7:57 PM
finance.yahoo.com logoINVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 22 at 7:57 PM
finance.yahoo.com logoSHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 21 at 7:47 PM
americanbankingnews.com logoLadenburg Thalmann Financial Services Analysts Give Stemline Therapeutics Inc (STML) a $41.00 Price Target
www.americanbankingnews.com - March 21 at 1:55 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - March 20 at 6:08 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - March 20 at 4:22 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Stemline Therapeutics Inc's FY2020 Earnings (STML)
www.americanbankingnews.com - March 20 at 12:19 PM
finance.yahoo.com logoStemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead ... - Yahoo Finance
finance.yahoo.com - March 19 at 8:45 AM

Social

Frequently Asked Questions for Stemline Therapeutics (NASDAQ:STML)

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) issued its earnings results on Monday, May, 9th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.08. The business earned $205.65 million during the quarter, compared to analyst estimates of $121.43 million. Stemline Therapeutics had a negative return on equity of 50.06% and a negative net margin of 4,058.44%.

When will Stemline Therapeutics make its next earnings announcement?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?

6 equities research analysts have issued 12-month target prices for Stemline Therapeutics' shares. Their predictions range from $11.00 to $41.00. On average, they anticipate Stemline Therapeutics' stock price to reach $26.80 in the next year.

What are analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • 1. Cowen and Company analysts commented, "STML announced that it has completed enrollment of SL-401’s pivotal study in BPDCN." (3/23/2017)
  • 2. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (2/9/2017)
  • 3. Jefferies Group LLC analysts commented, "We had a chance to host investor meetings with mgmt, which primarily focused on near-term SL-401 catalysts. In BPDCN, the focus was around the pot’l 2H16 meeting with FDA to determine the amount of data needed to submit a BLA. The company also presented incrementally updated data in BPDCN that was consistent with data from ASCO." (7/22/2016)

Are investors shorting Stemline Therapeutics?

Stemline Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totalling 1,593,549 shares, an increase of 16.2% from the March 15th total of 1,371,249 shares. Based on an average trading volume of 280,426 shares, the days-to-cover ratio is currently 5.7 days.

Who owns Stemline Therapeutics stock?

Stemline Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Columbus Circle Investors (1.20%), Wells Fargo & Company MN (0.08%) and Nationwide Fund Advisors (0.07%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman.

Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?

Stemline Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Nationwide Fund Advisors and Wells Fargo & Company MN.

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Stemline Therapeutics stock cost?

One share of Stemline Therapeutics stock can currently be purchased for approximately $8.90.

Stemline Therapeutics (STML) Chart for Saturday, April, 29, 2017

This page was last updated on 4/29/2017 by MarketBeat.com Staff